

UNCLASSIFIED

Exhibit R-2, RDT&E Budget Item Justification: PB 2016 Army										Date: February 2015		
Appropriation/Budget Activity 2040: Research, Development, Test & Evaluation, Army / BA 4: Advanced Component Development & Prototypes (ACD&P)					R-1 Program Element (Number/Name) PE 0603807A / Medical Systems - Adv Dev							
COST (\$ in Millions)	Prior Years	FY 2014	FY 2015	FY 2016 Base	FY 2016 OCO	FY 2016 Total	FY 2017	FY 2018	FY 2019	FY 2020	Cost To Complete	Total Cost
Total Program Element	-	17.524	23.647	31.962	-	31.962	35.423	29.235	28.704	34.008	Continuing	Continuing
808: DoD Drug & Vacc Ad	-	6.712	8.966	15.997	-	15.997	16.204	14.509	14.482	16.665	Continuing	Continuing
811: Mil HIV Vac&Drug Dev	-	0.532	1.077	0.965	-	0.965	0.839	1.002	1.023	1.053	Continuing	Continuing
836: Field Medical Systems Advanced Development	-	9.738	13.325	15.000	-	15.000	18.380	13.724	13.199	16.290	Continuing	Continuing
VS7: MEDEVAC Mission Equipment Package (MEP) - Adv Dev	-	0.542	0.279	-	-	-	-	-	-	-	0.404	1.225

A. Mission Description and Budget Item Justification

This program element (PE) funds development of medical materiel within the early system integration portion of the System Development and Demonstration phase of the acquisition life cycle using 6.4 funding. Program efforts support transition of promising Science and Technology candidate medical technologies (drugs, vaccines, medical devices, diagnostics, and mechanisms for detection and control of disease carrying insects) to larger scale testing in humans for safety and effectiveness. Programs are aligned to meet future force requirements identified within concept documents and organizational structures. This Program Element also provides funding for Food and Drug Administration (FDA) regulated human clinical trials to gain additional information about safety and effectiveness on the path to licensure for use in humans. The Projects supported by this PE are:

(PROJ 808) funds development of candidate medical countermeasures for infectious diseases of military relevance. Efforts include vaccines, drugs, diagnostic kits/ devices, and insect control measures. These funds support human clinical efficacy trials of the drug/vaccine in a larger group that are designed to assess performance and to continue safety assessments in a larger group of volunteers. Products from this project will transition to 849.

(PROJ 811) funds the development of military relevant human immunodeficiency virus (HIV) medical countermeasures. It provides funding for planning and conducting of human clinical trials in a group of healthy volunteers to assess the drug/vaccine for safety, tolerability, how the drug/vaccine is distributed, metabolized, and excreted from the body, and investigate the appropriate dose for therapeutic use. Products from this project will transition to Project 812.

(PROJ 836) funds the demonstration and validation of medical products for enhanced combat casualty care and follow-on care, including rehabilitation. This project also funds the human clinical trials that test the safety and effectiveness of biologics, devices and demonstration. Clinical trials are conducted in accordance with U.S. Food and Drug Administration (FDA) regulations. Products from this project will transition to 832.

(PROJ VS7) funds program upgrades, retrofits, trains, and sustains the fleet of Medical Evacuation legacy helicopters that continue to play a major role in Iraq and Afghanistan. The approved force design increased the number of air frames in the force from 12 to 15 aircraft for 37 MEDEVAC companies. All products from this project will transition to VS8 in FY16.

UNCLASSIFIED

Exhibit R-2, RDT&E Budget Item Justification: PB 2016 Army	Date: February 2015
---	----------------------------

Appropriation/Budget Activity 2040: <i>Research, Development, Test & Evaluation, Army I BA 4: Advanced Component Development & Prototypes (ACD&P)</i>	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>
---	--

This program is managed by U.S. Army Medical Materiel Development Activity (USAMMDA) and U.S. Army Medical Materiel Agency (USAMMA) of the US Army Medical Research and Materiel Command.

B. Program Change Summary (\$ in Millions)	<u>FY 2014</u>	<u>FY 2015</u>	<u>FY 2016 Base</u>	<u>FY 2016 OCO</u>	<u>FY 2016 Total</u>
Previous President's Budget	15.594	23.659	32.295	-	32.295
Current President's Budget	17.524	23.647	31.962	-	31.962
Total Adjustments	1.930	-0.012	-0.333	-	-0.333
• Congressional General Reductions	-	-0.012			
• Congressional Directed Reductions	-	-			
• Congressional Rescissions	-	-			
• Congressional Adds	-	-			
• Congressional Directed Transfers	-	-			
• Reprogrammings	2.231	-			
• SBIR/STTR Transfer	-0.301	-			
• Adjustments to Budget Years	-	-	-0.333	-	-0.333

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2016 Army										Date: February 2015		
Appropriation/Budget Activity 2040 / 4					R-1 Program Element (Number/Name) PE 0603807A / Medical Systems - Adv Dev				Project (Number/Name) 808 / DoD Drug & Vacc Ad			
COST (\$ in Millions)	Prior Years	FY 2014	FY 2015	FY 2016 Base	FY 2016 OCO	FY 2016 Total	FY 2017	FY 2018	FY 2019	FY 2020	Cost To Complete	Total Cost
808: DoD Drug & Vacc Ad	-	6.712	8.966	15.997	-	15.997	16.204	14.509	14.482	16.665	Continuing	Continuing
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

This project funds development of candidate medical countermeasures for infectious diseases of military relevance. These efforts are in: vaccines, drugs, diagnostic kits/devices, and determining if insects are infected with pathogenic organisms capable of infecting service members/preventive medicine measures. These funds support human clinical effectiveness (capacity to produce a desired size of an effect under ideal or optimal conditions) trials of the drug/vaccine in larger groups that are designed to assess how well the drug/vaccine works, and to continue safety assessments in a larger group of volunteers. Funding supports both technical evaluations and human clinical testing to assure the safety and effectiveness of medical diagnostic kits and devices. This work, which is performed in military laboratories or civilian pharmaceutical firms, is directed toward the prevention of disease, early diagnosis, and accelerated recovery time once diagnosed; to enhance battlefield readiness. All clinical trials are conducted in accordance with U.S. Food and Drug Administration (FDA) regulations, a mandatory obligation for all military products placed into the hands of medical providers or service members. Product development priorities are determined based upon four major factors: (1) the extent and threat of the disease within the Combatant Commands theater of operations, (2) the clinical severity of the disease, (3) the technical maturity of the proposed solution, and (4) the affordability of the solution (development and production).

B. Accomplishments/Planned Programs (\$ in Millions)

	FY 2014	FY 2015	FY 2016
Title: DoD Drug and Vaccine Advanced Development	6.712	8.966	15.997
Description: Funding is provided for the following effort in the development of candidate medical countermeasures for military relevant infectious disease.			
FY 2014 Accomplishments: Tropical Antileishmanial Cream (TLC, Paromomycin/Gentamicin): Completed site development efforts for Phase 3 New World pivotal safety and effectiveness clinical trial on a diverse population. Dengue Tetravalent Vaccine: Continued volunteer follow up and subsequent analysis of data from pivotal Phase 3 (safety and effectiveness in 10 countries, over 30000 volunteers) endemic region studies of Dengue Tetravalent Vaccine with commercial partner Sanofi Pasteur, provided Go/No Go decision for pursuit of compressed vaccination schedule for US traveler/military indication. Joint Biological Agent identification and Diagnostic System (JBAIDS): Completed Analysis of Alternatives (AoA) and requirements analysis helped to determine that The Dengue JBAIDS capability does not meet user needs; therefore, the project has been terminated. Leishmania Rapid Diagnostic Device (LRDD): Transitioned LRDD to Project 849 (Drugs and Vaccines - 6.5) after completion of the analytical testing and Good Manufacturing Practices manufacturing reviews. Preventive Medicine Products: These products for the control/mitigation of arthropod (insect) borne diseases field testing and evaluation were delayed for several product candidates to include: field deployable detection devices for Chikungunya, Rift Valley Fever, Sand Fly Fever, Crimean-Congo Fever, advanced arthropod collection devices, Saliva Capture RTA card, spatial repellents, and advanced pesticides. Infectious Disease Diagnostic: These products field testing and			

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2016 Army		Date: February 2015	
Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>	Project (Number/Name) 808 / <i>DoD Drug & Vacc Ad</i>	
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2014	FY 2015
<p>evaluation were delayed for several product candidates to include: Scrub Typhus, Rickettsiae, and Sand Fly Fever based on decrement due to poor disbursements in FY2012.</p> <p>FY 2015 Plans: Topical Antileishmanial Cream (TLC, Paromomycin/Gentamicin): Topical Antileishmanial Cream is expected to transition in FY14 to Project 849 (Drugs and Vaccines - 6.5) after completion of the site development efforts for Phase 3 New World clinical trial. Expanded Access Treatment Program will continue until FDA approved product is available. Dengue Tetravalent Vaccine: Dengue Tetravalent Vaccine transitioned in FY14 to Project 849 after completion of volunteer follow up and data analysis on pivotal Phase 3 safety and effectiveness clinical trials. Preventive Medicine Products: These products fall into the category military operational requirements and are Commercial-Off-The-Shelf (COTS). As such, they have moved to a more appropriate Program Element (PE 836 or 832) and will be listed as separate products when they are considered for military use.</p> <p>FY 2016 Plans: Dengue Tetravalent Vaccine: Will continue to fund Dengue Tetravalent Vaccine until FY18 for additional two-year volunteer follow-up and data analysis on pivotal Phase 3 safety and effectiveness clinical trials required by the Thai Ministry of Public Health. Infectious Disease Diagnostic: Products will transition from S&T in FY16. Will begin preparation for field testing and evaluation of several product candidates to include: Scrub Typhus, Rickettsiae, and Sand Fly Fever. Dengue Vaccine Block II: Products will transition from S&T in FY16. Will transition from Military Infectious Diseases S&T funding and prepare for Phase 2 safety and efficacy trial (24 to 300 subjects) of vaccine candidate in an adult/military population. Treatment for Resistant Wound Infections: Products will transition from S&T in FY16. Will transition from Military Infectious Diseases S&T funding and begin preparation for safety and efficacy trials of drug candidate for the Treatment for Resistant Wound Infections. Next Generation Malaria Prophylaxis: The IPT will initiate a retinal safety study in 2016 and will continue to prepare the protocols for any required soldier specific studies that is needed. Arthropod Control/Surveillance: Will begin preparation for field testing and evaluation of several product candidates to include: Scrub Typhus, Rickettsiae, and Sand Fly Fever. Hemorrhagic Fever w/Renal Syndrome: Transition from Military Infectious Diseases S&T delayed indefinitely based on lack of product maturity.</p>			
Accomplishments/Planned Programs Subtotals		6.712	8.966
C. Other Program Funding Summary (\$ in Millions)			
N/A			
Remarks			
D. Acquisition Strategy			
Test and evaluate in-house and commercially developed products in extensive government-managed clinical trials to gather data required for FDA licensure and Environmental Protection Agency registration.			

UNCLASSIFIED

PE 0603807A: *Medical Systems - Adv Dev*
Army

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2016 Army												Date: February 2015			
Appropriation/Budget Activity 2040 / 4						R-1 Program Element (Number/Name) PE 0603807A / Medical Systems - Adv Dev				Project (Number/Name) 808 / DoD Drug & Vacc Ad					
Management Services (\$ in Millions)				FY 2014		FY 2015		FY 2016 Base		FY 2016 OCO		FY 2016 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Medical Product Development Management Services Cost	Various	Not Applicable : Not applicable	15.451	1.939		0.965		1.280		-		1.280	Continuing	Continuing	Continuing
Medical Product Development Management Services Cost	PO	General Dynamics Information Technology, : Frederick MD	0.000	-		1.365		1.293		-		1.293	-	2.658	-
Subtotal			15.451	1.939		2.330		2.573		-		2.573	-	-	-
Product Development (\$ in Millions)				FY 2014		FY 2015		FY 2016 Base		FY 2016 OCO		FY 2016 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Medical Product Development Cost	Various	Not applicable : Not applicable	22.827	1.890		1.370		2.632		-		2.632	Continuing	Continuing	Continuing
Product Development of Malaria Prophylaxis	Various	Walter Reed Army Institute of Research : Silver Spring, MD	3.000	-		-		-		-		-	-	3.000	-
Product Development of Malaria Prophylaxis	Allot	Armed Forces Research Institute of Medical Sciences : Cambodia	0.000	2.111		-		-		-		-	-	2.111	-
Product Development of Malaria Prophylaxis	Allot	TBD : TBD	0.000	-		1.010		-		-		-	-	1.010	-
Subtotal			25.827	4.001		2.380		2.632		-		2.632	-	-	-
Support (\$ in Millions)				FY 2014		FY 2015		FY 2016 Base		FY 2016 OCO		FY 2016 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Medical Product Development Support Cost	Various	Not Applicable : Not applicable	9.204	0.448		1.097		2.545		-		2.545	Continuing	Continuing	Continuing

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2016 Army													Date: February 2015		
Appropriation/Budget Activity 2040 / 4						R-1 Program Element (Number/Name) PE 0603807A / Medical Systems - Adv Dev				Project (Number/Name) 808 / DoD Drug & Vacc Ad					
Support (\$ in Millions)				FY 2014		FY 2015		FY 2016 Base		FY 2016 OCO		FY 2016 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Subtotal			9.204	0.448		1.097		2.545		-		2.545	-	-	-
Test and Evaluation (\$ in Millions)				FY 2014		FY 2015		FY 2016 Base		FY 2016 OCO		FY 2016 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Medical Product Development T&E Cost	Various	Not applicable : Not applicable	44.718	0.324		1.160		5.047		-		5.047	Continuing	Continuing	Continuing
Malaria Prophylaxis clinical trial	TBD	TBD : TBD	0.000	-		1.999		3.200		-		3.200	-	5.199	-
Subtotal			44.718	0.324		3.159		8.247		-		8.247	-	-	-
			Prior Years	FY 2014		FY 2015		FY 2016 Base		FY 2016 OCO		FY 2016 Total	Cost To Complete	Total Cost	Target Value of Contract
Project Cost Totals			95.200	6.712		8.966		15.997		-		15.997	-	-	-
Remarks															

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2016 Army **Date:** February 2015

Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>	Project (Number/Name) 808 / <i>DoD Drug & Vacc Ad</i>
--	--	---

Event Name	FY 2014				FY 2015				FY 2016				FY 2017				FY 2018				FY 2019				FY 2020			
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
Topical Antileishmanial Cream Phase Expanded Access Treatment Program																												
Infectious Disease Diagnostics Assays Validation of point-of-care																												
Dengue Vaccine Block II Phase 2 safety and efficacy trial preparation/pe																												
Arthropod Control / Surveillance Process Validation																												
Treatment for Resistant Wound Infections Phase 2 safety and efficacy tr																												
Q Fever Vaccine IND and NDA package creation																												
D5P Next Generation Malaria Drug Clinical Studies																												
Oral Drug for Cutaneous Leishmaniasis Adult Indication Study																												

UNCLASSIFIED

Exhibit R-4A, RDT&E Schedule Details: PB 2016 Army			Date: February 2015
Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>	Project (Number/Name) 808 / <i>DoD Drug & Vacc Ad</i>	

Schedule Details

Events	Start		End	
	Quarter	Year	Quarter	Year
Topical Antileishmanial Cream Phase Expanded Access Treatment Program	2	2011	1	2017
Infectious Disease Diagnostics Assays Validation of point-of-care	1	2016	1	2022
Dengue Vaccine Block II Phase 2 safety and efficacy trial preparation/perform	1	2016	4	2019
Arthropod Control / Surveillance Process Validation	1	2016	1	2022
Treatment for Resistant Wound Infections Phase 2 safety and efficacy trial	1	2016	4	2019
Q Fever Vaccine IND and NDA package creation	1	2015	4	2016
D5P Next Generation Malaria Drug Clinical Studies	1	2016	4	2017
Oral Drug for Cutaneous Leishmaniasis Adult Indication Study	1	2016	4	2019

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2016 Army										Date: February 2015		
Appropriation/Budget Activity 2040 / 4					R-1 Program Element (Number/Name) PE 0603807A / Medical Systems - Adv Dev				Project (Number/Name) 811 / Mil HIV Vac&Drug Dev			
COST (\$ in Millions)	Prior Years	FY 2014	FY 2015	FY 2016 Base	FY 2016 OCO	FY 2016 Total	FY 2017	FY 2018	FY 2019	FY 2020	Cost To Complete	Total Cost
811: Mil HIV Vac&Drug Dev	-	0.532	1.077	0.965	-	0.965	0.839	1.002	1.023	1.053	Continuing	Continuing
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

This project funds development of militarily relevant human immunodeficiency virus (HIV) medical countermeasures. It provides funding for the planning and conducting of human clinical trials in a group of healthy volunteers to assess the drug/vaccine for safety, tolerability, how the drug/vaccine is distributed, metabolized, and excreted from the body, and to investigate the appropriate dose for therapeutic use. Development efforts are focused on militarily unique needs effecting manning, mobilization, and deployment.

The major contractor is Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, MD. Research efforts are coordinated with the National Institutes of Health.

B. Accomplishments/Planned Programs (\$ in Millions)

	FY 2014	FY 2015	FY 2016
Title: Military HIV Vaccine & Drug Development	0.532	1.077	0.965
Description: This project funds advanced development research to develop candidate HIV vaccines, assess their safety and effectiveness in evaluations with human subjects, and protect military personnel from risks associated with HIV infection.			
FY 2014 Accomplishments: Continued the three inter-related clinical trials (RV305, RV306, RV328) aimed at refining our understanding of immune responses elicited by the increment 1 HIV regional vaccine strategy. Analyzed laboratory interrogation of samples from trial participants. Refined vaccine administration schedule as well as clinical trial design based on data from clinical trials. Safety and effectiveness clinical trial RV305, examined the immune responses to secondary boost of increment 1 HIV regional vaccine. Safety and effectiveness clinical trial RV306, examined the intensive immune monitoring of Prime-Boost Vaccine. Safety and effectiveness clinical trial RV328, conducted intensive immune monitoring of AIDSVAXB/E Regional Vaccine with a large well controlled trial to test immunity of improved vaccine Boost Prime/Boost Regional study to confirm safety and effectiveness in a diverse population. Adjusted plan for Regional well-controlled clinical trial large enough to demonstrate vaccine effectiveness to initiate in FY14.			
FY 2015 Plans: Conduct analysis of samples from safety and effectiveness clinical trial RV305 including extensive evaluation of binding antibodies based on previously determined correlates of protection. In addition, novel findings in cellular immune responses in the stomach have driven new requirements for evaluation of cytotoxic T cell responses in the peripheral blood. Complete FY15 collection of late invasive samples for safety and effectiveness clinical trials RV306 and RV328; those samples have a requirement for			

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2016 Army		Date: February 2015	
Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>	Project (Number/Name) 811 / <i>Mil HIV Vac&Drug Dev</i>	
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2014	FY 2015
<p>immediate processing and analysis. Conclude FY15 RV306 and 328 with closing costs associated with the 5 clinical trial sites associated with those protocols.</p> <p><i>FY 2016 Plans:</i> In RV305 (a late boost study of RV144 vaccine recipients), coordination will be made for final data analyses and meetings with investigators as to how the data should be presented/published. Results of RV305 has resulted in a rollover study (RV305 amendment) which will provide an additional boost dose to selected vaccine recipients. Candidate vaccine trials RV306 (evaluation of different one-year boosts) and RV328 (study of AIDSVAX B/E alone) will continue to seek further immunogenicity data that will complement. Results observed in the first Phase III study to show efficacy (RV144/The Thai Trial). RV403 will continue in Mozambique, Uganda, and Thailand. This study will compare immune responses induced by the RV144 regimen using AIDSVAX B/E mixed with L(MPLA) [monophosphoryl lipid A w/ liposomes.</p>			
Accomplishments/Planned Programs Subtotals		0.532	1.077
C. Other Program Funding Summary (\$ in Millions)			
N/A			
Remarks			
D. Acquisition Strategy			
Test and evaluate commercially developed drug/vaccine candidates in government-managed trials.			
E. Performance Metrics			
N/A			

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2016 Army												Date: February 2015			
Appropriation/Budget Activity 2040 / 4						R-1 Program Element (Number/Name) PE 0603807A / Medical Systems - Adv Dev				Project (Number/Name) 811 / Mil HIV Vac&Drug Dev					
Management Services (\$ in Millions)				FY 2014		FY 2015		FY 2016 Base		FY 2016 OCO		FY 2016 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Medical Product Development Management Services Cost	TBD	Not Applicable : Not Applicable	1.953	0.165		0.146		0.110		-		0.110	Continuing	Continuing	Continuing
Subtotal			1.953	0.165		0.146		0.110		-		0.110	-	-	-
Remarks Not Applicable															
Product Development (\$ in Millions)				FY 2014		FY 2015		FY 2016 Base		FY 2016 OCO		FY 2016 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Medical Product Development Cost	TBD	Not applicable : Not applicable	3.192	0.097		0.549		0.343		-		0.343	Continuing	Continuing	Continuing
Medical Product Development Support Cost	TBD	TBD : TBD	0.000	-		-		0.222		-		0.222	-	0.222	-
Subtotal			3.192	0.097		0.549		0.565		-		0.565	-	-	-
Support (\$ in Millions)				FY 2014		FY 2015		FY 2016 Base		FY 2016 OCO		FY 2016 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Medical Product Development Support Cost	TBD	TBD : TBD	1.471	0.101		0.250		0.195		-		0.195	-	2.017	-
Subtotal			1.471	0.101		0.250		0.195		-		0.195	-	2.017	-
Remarks Not Applicable															

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2016 Army												Date: February 2015			
Appropriation/Budget Activity 2040 / 4						R-1 Program Element (Number/Name) PE 0603807A / Medical Systems - Adv Dev				Project (Number/Name) 811 / Mil HIV Vac&Drug Dev					

Test and Evaluation (\$ in Millions)				FY 2014		FY 2015		FY 2016 Base		FY 2016 OCO		FY 2016 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Medical Product Development T&E Cost	TBD	Not applicable : Not Applicable	15.607	0.169		0.132		0.095		-		0.095	-	16.003	-
Subtotal			15.607	0.169		0.132		0.095		-		0.095	-	16.003	-

Remarks Not Applicable															
----------------------------------	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

	Prior Years	FY 2014		FY 2015		FY 2016 Base		FY 2016 OCO		FY 2016 Total	Cost To Complete	Total Cost	Target Value of Contract
Project Cost Totals	22.223	0.532		1.077		0.965		-		0.965	-	-	-

Remarks															
----------------	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2016 Army **Date:** February 2015

Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>	Project (Number/Name) 811 / <i>Mil HIV Vac&Drug Dev</i>
--	--	---

Event Name	FY 2014				FY 2015				FY 2016				FY 2017				FY 2018				FY 2019				FY 2020			
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
RV305 Immune Responses to Secondary Boost of Regional Vaccine																												
RV306 Intensive Immune Monitoring of Prime-Boost Vaccine																												
RV328 Intensive Immune Monitoring of AIDSVAXB/E alone	FY12-FY17																											
RV403 to evaluate adjuvant's ability to enhance durability of vaccine can	FY15-FY17																											

UNCLASSIFIED

Exhibit R-4A, RDT&E Schedule Details: PB 2016 Army			Date: February 2015
Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>	Project (Number/Name) 811 / <i>Mil HIV Vac&Drug Dev</i>	

Schedule Details

Events	Start		End	
	Quarter	Year	Quarter	Year
RV305 Immune Responses to Secondary Boost of Regional Vaccine	1	2013	4	2014
RV306 Intensive Immune Monitoring of Prime-Boost Vaccine	2	2011	4	2015
RV328 Intensive Immune Monitoring of AIDSVAXB/E alone	4	2014	4	2017
RV403 to evaluate adjuvant's ability to enhance durability of vaccine candidate	2	2015	4	2017

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2016 Army										Date: February 2015		
Appropriation/Budget Activity 2040 / 4					R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>				Project (Number/Name) 836 / <i>Field Medical Systems Advanced Development</i>			
COST (\$ in Millions)	Prior Years	FY 2014	FY 2015	FY 2016 Base	FY 2016 OCO	FY 2016 Total	FY 2017	FY 2018	FY 2019	FY 2020	Cost To Complete	Total Cost
836: <i>Field Medical Systems Advanced Development</i>	-	9.738	13.325	15.000	-	15.000	18.380	13.724	13.199	16.290	Continuing	Continuing
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

Note
Not applicable for this PE.

A. Mission Description and Budget Item Justification
This project funds the demonstration and validation of medical products for enhanced combat casualty care and follow-on care, including rehabilitation. This project funds human clinical trials to test the safety and effectiveness of biologics (products derived from living organisms) and devices necessary to meet medical requirements. When available, commercial-off-the-shelf (COTS) medical products are also tested and evaluated for transition to engineering and manufacturing development. Consideration is also given to reducing the medical logistics footprint through smaller weight, volume, and equipment independence from supporting materials. All clinical trials are conducted in accordance with U.S. Food and Drug Administration (FDA) regulations.

B. Accomplishments/Planned Programs (\$ in Millions)	FY 2014	FY 2015	FY 2016
Title: Field Medical Systems Advanced Development - PM Medical Devices Description: Advanced Concept Development funding is provided for the following development of medical devices in support of enhanced combat casualty care. FY 2014 Accomplishments: Eye Tracking System for Assessing Concussions (system is a traumatic brain injury diagnostic tool): Re-baselined, as a Request for Information (RFI) was submitted in FY12 to reevaluate the most current devices and no Research Development Test Evaluation (RDTE) funds were needed in FY14. Traumatic Brain Injury (TBI) Diagnostic Assay System Increment II Point of Care Device enter pivotal clinical trial for safety and effectiveness and transition to engineering and manufacturing funding in project 832. Increment III of the TBI Diagnostic Assay System has been delayed and did not reach milestone B (proof of concept) in FY14 based on the maturity of the technology. TBI Diagnostic Assay System Increment II Point of Care Device: TBI Diagnostic Assay System Increment II Point of Care Device entered pivotal clinical trial for safety and effectiveness and transition to engineering and manufacturing funding in project 832. Increment III of the TBI Diagnostic Assay System has been delayed and will not reach milestone B (proof of concept) in FY14 based on the maturity of the technology. Impedance Threshold Device for the Treatment of TBI: Current device has a 510(k) (Premarket Notification) clearance for multiple indications. Submission of a new 510(k) to	9.662	11.791	11.760

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2016 Army		Date: February 2015		
Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / Medical Systems - Adv Dev	Project (Number/Name) 836 / Field Medical Systems Advanced Development		
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2014	FY 2015	FY 2016
cover the expanded indications for the currently fielded device. Device will no longer be a stand-alone product, because the capability will be incorporated in existing ventilators. FY 2015 Plans: Eye Tracking System for Assessing Concussions (system is a traumatic brain injury diagnostic tool): Noninvasive neurodiagnostic technologies for TBI is multi-focused. The Eye Tracking System for Assessing Concussions (system is a traumatic brain injury diagnostic tool) is one of multiple systems to be evaluated. Efforts to collate all non-invasive technologies into one integrated IPT is currently in place. The 3 technologies currently involved are the Eye- Tracking System, the Quantitative electroencephalogram (qEEG) and Balance Platforms. Future components of the multi-focused approach will fall under the scope of this line item. No Research Development Test Evaluation (RDTE) funds are needed for FY15. This project line is being programmed in FY16-20 plan under non-invasive neurodiagnostic line item. TBI Diagnostic Assay System Increment II Point of Care Device: TBI Diagnostic Assay System: The focus of this effort will be to use the current Biomarker technology developed by Banyan and cross-level all known technologies to Abbott Diagnostics. Contracting efforts are in place to facilitate this path forward. Army currently uses the i-STAT in assemblages. The intent of this effort is to modernize the i-STAT platform to accommodate the new cartridges associated with the TBI Biomarkers. Impedance Threshold Device for the Treatment of TBI: Current device has a 510(k) (Premarket Notification) clearance for multiple indications. Continue the submission of a new 510(k) is planned to cover the expanded indications for the currently fielded device. Device will no longer be a stand-alone product, because the capability will be incorporated in existing ventilators. Compartment Syndrome Pressure Device: Transition from project 840 6.3 funding and enroll patients in the pivotal trial for FDA clearance for anticipated FY15 start of the clinical trial. FY 2016 Plans: TBI Diagnostic Assay System Increment II Point of Care Device: TBI Diagnostic Assay System: Will continue current Biomarker technology developed by Banyan and cross-level all known technologies to Abbott Diagnostics. Contracting efforts will continue through FY16. Impedance Threshold Device for the Treatment of TBI: Product has transitioned back to S&T to conduct research on the expanded indications for the fielded device. Compartment Syndrome Pressure Device: Compartment Syndrome Pressure Device will be delayed for transition into Advanced Development from S&T until FY17. Milestone A will be delayed until FY17. After the Milestone A, product will transition into Advanced Development. Junctional / Noncompressible Hemorrhage Control Agent: Junctional / Noncompressible Hemorrhage Control Agent: Product will transition into Advanced Development after Milestone B in late FY15. If FDA requires 510-K, program will develop required paper work for submission to the FDA.				
Title: Field Medical Systems Advanced Development - PM Medical Support Systems		0.076	1.534	3.240
Description: Funding is provided for the following effort in the development of products that support the medical mission in combat casualty care and health care operations.				
FY 2014 Accomplishments:				

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2016 Army			Date: February 2015		
Appropriation/Budget Activity 2040 / 4		R-1 Program Element (Number/Name) PE 0603807A / Medical Systems - Adv Dev		Project (Number/Name) 836 / Field Medical Systems Advanced Development	
B. Accomplishments/Planned Programs (\$ in Millions)			FY 2014	FY 2015	FY 2016
<p>Environmental Sentinel Biomonitor: Continued development of the Environmental Sentinel Biomonitor (ESB) and transitioned to project 832. The ESB will assist preventive medicine personnel certify water capabilities by providing a presumptive screening capability that can rapidly identify toxicity in water. Medical Evac and Treatment Vehicles Medical Equipment Set and Mission Essential Package: Continued collaboration with Program Executive Office Combat Support/Combat Service Support (PEO CS&CSS) and Program Executive Office Ground Combat Systems (PEO GCS) on development efforts for emerging medical vehicle evacuation/casualty evacuation (CASEVAC) variants. Medical variants that were collaborated on with PEO CS/CSS consisted of medical shelters, Mine Resistant Ambush Protected (MRAP), Armored Multipurpose Vehicle (AMPV), and Joint Light Tactical Vehicle (JLTV). Collaborated with PEO GCS on medical variants for the Heavy Brigade Combat Team (HBCT). Improved Vector Tent Traps: Developed prototypes of Vector Tent Traps for testing after transition from S&T. The Vector Tent Trap allows researchers to safely conduct vector surveillance on insects that are attracted to humans and vector-borne diseases. Altitude Readiness Management System (ARMS): Began the development of the Altitude Readiness Management System (ARMS). ARMS transitioned from S&T MM3 funding line. The ARMS product is a handheld sensor and software decision device to plan, monitor, and manage unit altitude illness risk and task performance prediction. Hydration Status Monitor (HSM): Planned to transition Hydration Status Monitor (HSM) from project MM3 6.3 funding to prepare for milestone B (proof of concept) and down-select. The HSM product will accurately detect the hydration status of Soldiers.</p> <p>FY 2015 Plans:</p> <p>Medical Evac and Treatment Vehicles Medical Equipment Set and Mission Essential Package: Continue collaboration with Program Executive Office Combat Support/Combat Service Support (PEO CS&CSS) and Program Executive Office Ground Combat Systems (PEO GCS) on development efforts for emerging medical vehicle evacuation/casualty evacuation (CASEVAC) variants. Improved Vector Tent Traps: Continue prototype development of Vector Tent Traps and transition to project 832. Altitude Readiness Management System (ARMS): Continue prototype development of the Altitude Readiness Management System (ARMS) and transition to project 832. Next Generation Uniform Repellent: Begin development of the Next Generation Uniform Repellent (NGUR). The NGUR transitions from an S&T SBIR. The NGUR is an effort to develop new military uniform insect repellent formulations for the uniform materiel and the corresponding uniform treatment technology. Next Generation Immobilization System: Transition from S&T SBIR. Develop prototypes for initial developmental testing and FDA data collection. The Next Generation Immobilization System (NGIS) provides advanced vibration dampening to allow for safer evacuation of spinal cord injury and traumatic brain injury casualties. Hydration Status Monitor (HSM): Hydration Status Monitor (HSM) transition continues to be delayed. Milestone B for this effort is scheduled for Feb 2015. Contract is planned to be a 4 year effort to develop the actual device and gain FDA approval for use.</p> <p>FY 2016 Plans:</p> <p>Medical Evac and Treatment Vehicles Medical Equipment Set and Mission Essential Package: Will continue collaboration with Program Executive Office Combat Support/Combat Service Support (PEO CS&CSS) and Program Executive Office Ground Combat Systems (PEO GCS) on development efforts for emerging medical vehicle evacuation/casualty evacuation (CASEVAC)</p>					

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2016 Army		Date: February 2015	
Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>	Project (Number/Name) 836 / <i>Field Medical Systems Advanced Development</i>	
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2014	FY 2015
variants including AMPV source selection. CASEVAC kit development for MRAP Dash and JLTV vehicles will be explored. Will transition to 832 in FY17. Next Generation Uniform Repellent: Will continue development of the Next Generation Uniform Repellent/Impregnation process in collaboration with PEO Soldier. Will obtain EPA registration. Will perform cut and sew testing of EPA approved uniform repellent/impregnation process for permethrin. Will investigate use of other repellents. Next Generation Immobilization System (NGIS): Will continue prototype development of NGIS and begin initial developmental tests and user evaluations. Hydration Status Monitor (HSM): Hydration Status Monitor (HSM) transition will be delayed until FY16 due to a more extensive feasibility study than initially determined. Milestone B for this effort is scheduled for 2QFY16. Will begin to develop prototype devices and prepare for the Milestone B submission with required documentation.			
Accomplishments/Planned Programs Subtotals		9.738	13.325
C. Other Program Funding Summary (\$ in Millions)			
N/A			
Remarks			
D. Acquisition Strategy			
Develop in-house or industrial prototypes in government-managed programs to meet military and regulatory requirements for production and fielding.			
E. Performance Metrics			
N/A			

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2016 Army												Date: February 2015			
Appropriation/Budget Activity 2040 / 4						R-1 Program Element (Number/Name) PE 0603807A / Medical Systems - Adv Dev				Project (Number/Name) 836 / Field Medical Systems Advanced Development					
Management Services (\$ in Millions)				FY 2014		FY 2015		FY 2016 Base		FY 2016 OCO		FY 2016 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Medical Product Development Management Services Cost	Various	Not Applicable : Not applicable	40.231	0.024		0.933		0.623		-		0.623	Continuing	Continuing	Continuing
TBI Diagnostic Assay System - Increment II (benchtop/POC/ Bandits)	TBD	Banyan BioMarkers, Inc : Alachua FL	0.000	0.208		-		-		-		-	-	0.208	-
Impedance Threshold Device for the Treatment of Traumatic Brain Injury	TBD	Advance Circulatory Systems, Inc : Roseville, MN	0.000	0.154		-		-		-		-	-	0.154	-
Subtotal			40.231	0.386		0.933		0.623		-		0.623	-	-	-
Product Development (\$ in Millions)				FY 2014		FY 2015		FY 2016 Base		FY 2016 OCO		FY 2016 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Product Development	TBD	TBD : TBD	0.000	-		0.932		-		-		-	-	0.932	-
Product Development	TBD	Banyan BioMarkers, Inc : Alachua FL	31.514	-		-		-		-		-	Continuing	Continuing	Continuing
Product Development	TBD	HemCon Medical Technologies : Tigard, Oregon	9.720	-		-		-		-		-	Continuing	Continuing	Continuing
Development of Platelet Derived Hemostatic agent	TBD	Fast Track Drugs & Biologics : Frederick, MD	1.800	-		-		-		-		-	Continuing	Continuing	Continuing
Medical Product Development	TBD	ALL Product : Various	1.931	-		-		-		-		-	Continuing	Continuing	Continuing
Product Development of Freeze-dried plasma	TBD	TBD : TBD	2.400	-		6.884		-		-		-	Continuing	Continuing	Continuing
Point of Care Coagulation Profiler	TBD	TBD : TBD	0.000	-		-		0.385		-		0.385	-	0.385	-

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2016 Army												Date: February 2015			
Appropriation/Budget Activity 2040 / 4						R-1 Program Element (Number/Name) PE 0603807A / Medical Systems - Adv Dev				Project (Number/Name) 836 / Field Medical Systems Advanced Development					
Product Development (\$ in Millions)				FY 2014		FY 2015		FY 2016 Base		FY 2016 OCO		FY 2016 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
TBI Diagnostic Assay System - Increment II (benchtop/POC/ Bandits)	TBD	Banyan BioMarkers, Inc : Alachua FL	0.000	6.737		-		6.614		-		6.614	-	13.351	-
Impedance Threshold Device for the Treatment of Traumatic Brain Injury	TBD	Advance Circulatory Systems Inc. : Roseville, MN	0.000	2.322		-		-		-		-	-	2.322	-
Compartment Syndrome Pressure Device	TBD	Twinstar : Minniapolis, MN	0.000	-		1.871		-		-		-	-	1.871	-
Hydration Status Monitor	TBD	Gaia Medical : LaJolla CA	0.000	-		0.841		-		-		-	-	0.841	-
Noninvasive Neuromodulator TBI	TBD	TBD : TBD	0.000	-		-		2.140		-		2.140	-	2.140	-
Field Sterilizer	TBD	TBD : TBD	0.000	-		-		3.815		-		3.815	-	3.815	-
Subtotal			47.365	9.059		10.528		12.954		-		12.954	-	-	-
Support (\$ in Millions)				FY 2014		FY 2015		FY 2016 Base		FY 2016 OCO		FY 2016 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Medical Product Development Support Cost	Various	Not Applicable : Not applicable	43.865	0.200		0.932		0.723		-		0.723	Continuing	Continuing	Continuing
Subtotal			43.865	0.200		0.932		0.723		-		0.723	-	-	-
Remarks															
No product/contract costs greater than \$1M individually.															
Test and Evaluation (\$ in Millions)				FY 2014		FY 2015		FY 2016 Base		FY 2016 OCO		FY 2016 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Medical Product Development T&E Cost	TBD	Not applicable : Not applicable	35.968	0.093		0.932		0.700		-		0.700	Continuing	Continuing	Continuing

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2016 Army												Date: February 2015		
Appropriation/Budget Activity 2040 / 4						R-1 Program Element (Number/Name) PE 0603807A / Medical Systems - Adv Dev				Project (Number/Name) 836 / Field Medical Systems Advanced Development				

Test and Evaluation (\$ in Millions)				FY 2014		FY 2015		FY 2016 Base		FY 2016 OCO		FY 2016 Total				
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost		Cost To Complete	Total Cost	Target Value of Contract
Subtotal			35.968	0.093		0.932		0.700		-		0.700		-	-	-

Remarks No product/contract costs greater than \$1M individually.																
---	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

	Prior Years	FY 2014		FY 2015		FY 2016 Base		FY 2016 OCO		FY 2016 Total	Cost To Complete	Total Cost	Target Value of Contract
Project Cost Totals	167.429	9.738		13.325		15.000		-		15.000	-	-	-

Remarks																
----------------	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2016 Army																		Date: February 2015										
Appropriation/Budget Activity										R-1 Program Element (Number/Name)								Project (Number/Name)										
2040 / 4										PE 0603807A / Medical Systems - Adv Dev								836 / Field Medical Systems Advanced Development										
Event Name	FY 2014				FY 2015				FY 2016				FY 2017				FY 2018				FY 2019				FY 2020			
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
(1) Cryopreserved Platelets (CPP) Critical Design Review MS-B				1																								
				MS-B																								
Cryopreserved Platelets (CPP) Phase 1 Safety Clinical Trial																												
				Phase 1 Safety Clinical Trial																								
(2) Bench-top/POC Biomarker assay for determining exposure to Trauma				2																								
				MS-B																								
Impedance Threshold Device for the Treatment of TBI (PreMarket Note.)																												
				510(k) submittal for new indications																								
(3) Hydration Status Monitor MS-B																												
(4) Noninvasive Neuromodulator TBI MS-A																												

UNCLASSIFIED

Exhibit R-4A, RDT&E Schedule Details: PB 2016 Army			Date: February 2015
Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>	Project (Number/Name) 836 / <i>Field Medical Systems Advanced Development</i>	

Schedule Details

Events	Start		End	
	Quarter	Year	Quarter	Year
Cryopreserved Platelets (CPP) Critical Design Review MS-B	4	2014	4	2014
Cryopreserved Platelets (CPP) Phase 1 Safety Clinical Trial	4	2011	3	2014
Bench-top/POC Biomarker assay for determining exposure to Traumatic Brain Injury	1	2014	1	2014
Impedance Threshold Device for the Treatment of TBI (PreMarket Note.)	3	2013	2	2014
Hydration Status Monitor MS-B	4	2015	4	2015
Noninvasive Neuromodulator TBI MS-A	4	2014	4	2014

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2016 Army										Date: February 2015		
Appropriation/Budget Activity 2040 / 4					R-1 Program Element (Number/Name) PE 0603807A / Medical Systems - Adv Dev				Project (Number/Name) VS7 / MEDEVAC Mission Equipment Package (MEP) - Adv Dev			
COST (\$ in Millions)	Prior Years	FY 2014	FY 2015	FY 2016 Base	FY 2016 OCO	FY 2016 Total	FY 2017	FY 2018	FY 2019	FY 2020	Cost To Complete	Total Cost
VS7: MEDEVAC Mission Equipment Package (MEP) - Adv Dev	-	0.542	0.279	-	-	-	-	-	-	-	0.404	1.225
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		
Note Medical Evacuation Enroute Care Validation Study is completed in FY 2015.												
A. Mission Description and Budget Item Justification Original models of Army Black Hawk MEDEVAC helicopters continue to play a major role in maintaining high US troop survival rates in Iraq and Afghanistan by evacuating wounded troops in less than one-hour. In 2009 a VCSA-approved force design update increased the number of air frames in the force from 12 to 15 aircraft for 37 MEDEVAC companies to better meet operational needs. In 2010, the AMEDD accepted life-cycle management of the MEDEVAC MEP from PEO Aviation. In order to achieve required operational capability and enhance commonality across the MEDEVAC fleet, the MEDEVAC MEP program upgrades, retrofits, trains, and sustains the 256 MEDEVAC legacy helicopters to achieve the medical capability provided by the HH-60M, which is factory built for the MEDEVAC mission.												
B. Accomplishments/Planned Programs (\$ in Millions)									FY 2014	FY 2015	FY 2016	
Title: Telemedicine for MEDEVAC aircraft Description: Effort is focused on requirement to provide enroute patient data to treatment facilities. FY 2014 Accomplishments: Continue design, development, and testing of the telemedicine systems in order to provide medics with state of the art capability to monitor and communicate patient data to ground crews at forward treatment facility.									0.542	-	-	
Title: Medical Evacuation Enroute Care Validation Study Description: Medical Evacuation Enroute Care Validation Study FY 2015 Plans: Modify Interim MEDEVAC Mission Support System (IMMSS) to take into account the new paramedic skills being used by the flight paramedic.									-	0.279	-	
Accomplishments/Planned Programs Subtotals									0.542	0.279	-	
C. Other Program Funding Summary (\$ in Millions) N/A												

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2016 Army		Date: February 2015
Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / Medical Systems - Adv Dev	Project (Number/Name) VS7 / MEDEVAC Mission Equipment Package (MEP) - Adv Dev
C. Other Program Funding Summary (\$ in Millions)		
<u>Remarks</u>		
D. Acquisition Strategy Develop in-house or industrial prototypes in government-managed programs to meet military MEDEVAC and regulatory requirements for production and fielding.		
E. Performance Metrics N/A		

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2016 Army												Date: February 2015			
Appropriation/Budget Activity 2040 / 4						R-1 Program Element (Number/Name) PE 0603807A / Medical Systems - Adv Dev				Project (Number/Name) VS7 / MEDEVAC Mission Equipment Package (MEP) - Adv Dev					
Management Services (\$ in Millions)				FY 2014		FY 2015		FY 2016 Base		FY 2016 OCO		FY 2016 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Medical Product Development Management Services Cost	TBD	APM MEDEVAC : Huntsville, AL	0.189	-		-		-		-		-	-	0.189	-
Subtotal			0.189	-		-		-		-		-	-	0.189	-
Product Development (\$ in Millions)				FY 2014		FY 2015		FY 2016 Base		FY 2016 OCO		FY 2016 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Medical Product Development Cost	TBD	APM MEDEVAC PEO Aviation : Huntsville AL	1.479	-		-		-		-		-	-	1.479	-
Subtotal			1.479	-		-		-		-		-	-	1.479	-
Support (\$ in Millions)				FY 2014		FY 2015		FY 2016 Base		FY 2016 OCO		FY 2016 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Medical Product Development Support Cost	TBD	APM MEDEVAC : Huntsville, AL	0.100	0.542		0.279		-		-		-	-	0.921	-
Subtotal			0.100	0.542		0.279		-		-		-	-	0.921	-
Test and Evaluation (\$ in Millions)				FY 2014		FY 2015		FY 2016 Base		FY 2016 OCO		FY 2016 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Medical Product Development T&E Cost	MIPR	APM MEDEVAC PEO Aviation : Huntsville, AL	0.199	-		-		-		-		-	-	0.199	-
Subtotal			0.199	-		-		-		-		-	-	0.199	-

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2016 Army											Date: February 2015				
Appropriation/Budget Activity 2040 / 4					R-1 Program Element (Number/Name) PE 0603807A / Medical Systems - Adv Dev				Project (Number/Name) VS7 / MEDEVAC Mission Equipment Package (MEP) - Adv Dev						
			Prior Years	FY 2014		FY 2015		FY 2016 Base		FY 2016 OCO		FY 2016 Total	Cost To Complete	Total Cost	Target Value of Contract
Project Cost Totals			1.967	0.542		0.279		-		-		-	-	2.788	-

Remarks

UNCLASSIFIED

PE 0603807A: *Medical Systems - Adv Dev*
Army

R-1 Line #68

R-1 Program Element (Number/Name)
PE 0603807A / Medical Systems - Adv Dev

Project (Number/Name)
VS7 I MEDEVAC Mission Equipment
Package (MEP) - Adv Dev

Event Name	FY 2014				FY 2015				FY 2016				FY 2017				FY 2018				FY 2019				FY 2020			
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
Telemedicine Research and Development and Tech transfer	Research and development																											
Medical Evacuation Enroute Care Validation Study																												

UNCLASSIFIED

Exhibit R-4A, RDT&E Schedule Details: PB 2016 Army			Date: February 2015
Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>	Project (Number/Name) VS7 / <i>MEDEVAC Mission Equipment Package (MEP) - Adv Dev</i>	

Schedule Details

Events	Start		End	
	Quarter	Year	Quarter	Year
Telemedicine Research and Development and Tech transfer	1	2012	4	2015
Medical Evacuation Enroute Care Validation Study	3	2013	4	2014